首页 | 本学科首页   官方微博 | 高级检索  
     


Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer
Affiliation:1. Oncology Department, Centre Léon Bérard, Lyon, France;2. Oncology Department, Institut Claudius Regaud, Toulouse, France;3. Department of Clinical Research and Innovation, Centre Léon Bérard, Lyon, France;4. Oncology Department, Curie Site Paris, Paris, France;5. Oncology Department, Centre Francois Baclesse, Caen, France;6. Oncology Department, Curie Site Saint-Cloud, Saint-Cloud, France;7. Oncology Department, Institut de Cancérologie de la Loire Lucien Neuwir, Saint-Priest-en-Jarez, France;8. Oncology Department, Institut Sainte Catherine, Avignon, France;9. Oncology Department, Chu de Limoges - Hopital Dupuytren, Limoges, France;10. Oncology Department, Royal Stoke Hospital, Stoke-on-Trent, UK;11. Oncology Department, Institut de Cancérologie de l''Ouest Site Rene Gauducheau, Saint-Herblain, France;12. Oncology Department, Hopitaux du Leman - Site Georges Pianta, Thonon-les-Bains, France;13. Oncology Department, Institut Bergonié, Bordeaux, France;14. Oncology Department, Centre CARIO - HPCA, Plérin sur Mer, France;15. Oncology Department, Hopital Saint Louis, Paris, France;16. Clinical Trials and Statistics Unit, ICR - The Institute of Cancer Research, London, UK;17. Oncology Department, Centre Hospitalier Notre Dame et Reine Fabiola - Grand Hopital de Charleroi, Charleroi, Belgium;18. R&D Department, UNICANCER - UCBG, Le Kremlin-Bicêtre, France;19. Oncology Department, Western General Hospital, Edinburgh, UK;20. Oncology Department, Gustave Roussy, Villejuif, France
Abstract:
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号